Because of this drug, a 67-year-old woman died of severe skin necrosis

That one Alarming security information Published by the National Medicines Agency on January 11. The cause is toxic epidermal necrolysis (also called “Lyle’s syndrome”). Fatal was reported in A 67-year-old woman treatment by adagrasib (Krazati®) for cancer the lungs (not a small cell). Epidermal necrolysis is one form The most severe allergic manifestationsMainly caused and characterized by taking drugs Brutal destruction of the epidermis and mucous membranes (oral, vaginal, conjunctiva, etc.). The analysis made it possible to identify four other cases Severe skin reactions

and one non-serious case of “skin toxicity” related to the use of adagrasib alone or in combination. “Additional investigation is underway to evaluate this signal and take appropriate action” Reports to ANSM.

These skin symptoms should alert

Epidermal necrolysis is very rare, recalls the high authority of health – 2 to 6 cases per million inhabitants per year – and is an important emergency. Affected patients taking adagrasib, as part of a compassionate access program or clinical trial, should consult a doctor if they experience it. Symptoms of skin toxicityEspecially:

• a the pain normal skin;
• A rash that spreads quickly;
• skin blisters and/or large areas of peeling skin;
• Inflammation and then hemorrhagic erosions on mucous membranes including mouth, nose, eyes, anus and genital areas.

Can cause necrosis Start insidiously and uncertainly.

Any early mucosal damage (conjunctivitis, Pharyngitis) fever after recent drug introduction, especially a High risk drug Like adagrasib. should be treated with adagrasib Discontinue immediately if Stevens-Johnson syndrome is suspected (SJS) or lile or bullous lesions and the patient should be referred to a dermatologist immediately. Treatment should be permanently discontinued if a diagnosis of SJS or Lyell’s is confirmed.

Benefits of Krazati® medicine a Marketing authorization in the United States Patients with advanced non-small cell lung cancer carrying the KRAS G12C mutation. On November 9, 2023, the European Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for a placing the drug on the European market, In the same sign. The opinion of the European Commission is pending. Currently, there is adagrasib Available in France As part of the Compassionate Access Program. Compassionate use programs allow therapeutic use of drugs without marketing authorization Dead end patients

The FDA has temporarily suspended the initiation of new treatments with adagrasib under these programs.